Taner Tan

Dr. Taner Tan

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2025 in British Journal of Haematology
Verified
Journal Article
Open access
UYUmut Yılmaz
Umut Yılmaz
EDEsra Terzi Demirsoy
Esra Terzi Demirsoy
FKFatma Keklik Karadağ
Fatma Keklik Karadağ
UHUğur Hatipoğlu
Uğur Hatipoğlu
MMMeral Uluköylü Mengüç
Meral Uluköylü Mengüç
BFBurhan Ferhanoğlu
Burhan Ferhanoğlu
Summary: Comparative first‐line trials in large B‐cell lymphoma (LBCL) have mostly failed over the last decade. Failures were commonly attributed to overestimation of the progression risk for the control arms, bringing the precision of the international prognostic index (IPI) into scrutiny. Simplified molecular IPI (smIPI), introduced at American Society of Hematology 2023, was developed to address the shortcomings of IPI. This study investigated smIPI and its potential implications as trial eligibility criteria among a multicentre LBCL cohort of 1439 patients. Patients diagnosed between 2012 and 2024 were included. Data were collected from institutional archives. The primary end‐point was risk stratification for progression‐free survival (PFS). Kaplan–Meier and Cox regression methods were used for survival analyses. The smIPI reclassified 38.2% and 5.3% of patients to higher and lower risk groups from IPI, respectively. Patients reclassified to higher risk groups by smIPI had an increased risk of progression than the rest of the group (hazard ratio = 1.34, p = 0.003). High‐risk groups classified by IPI and smIPI had similar outcomes (3‐year PFS 54.9% vs. 56.3%); however, the high‐risk group size was expanded by 35.2% when defined by smIPI. The smIPI is easily applicable and more sensitive than IPI in identifying patients under high risk of progression who are ideal candidates to participate in clinical research.

30 May 2023 in Turkish Journal of Hematology
Verified
Journal Article
Open access
NYNese Yeldir
Nese Yeldir
TTTaner Tan
Taner Tan
OAOlga Meltem Akay
Olga Meltem Akay
İDİbrahim Öner Doğan
İbrahim Öner Doğan

1 August 2024 in Journal of Current Hematology & Oncology Research
Verified
Journal Article
Open access
PDF file
TTTaner Tan
Taner Tan
MAMEHMET AĞIRBAŞLI
MEHMET AĞIRBAŞLI
PAI-1 is an important factor in the fibrinolytic system. It is also involved in the etiopathogenesis of atherosclerotic processes, metabolic syndrome, obesity, and a significant number of solid and some of the hematological malignancies and even has valuable prognostic value. In this article, we review involvement of PAI-1 in areas other than the fibyrinolytic system, its roles, and its potential contribution to regulatory mechanisms and inhibition pathways. Many important studies proved that PAI-1 is significantly increased in obesity, metabolic syndrome, a significant proportion of malignancies. Although cell culture studies, in vivo studies and animal experiments have provided data on PAI-1 inhibition and models that block the pathways through which PAI-1 is metabolized and acts, suggesting that this blockade can reverse tumor progression, improve metabolic syndrome parameters and improve atherosclerotic processes, the results of these inhibitory agents in humans are still unknown and worth investigating. The upcoming phase 1-2 studies will answer these questions.

7 November 2025 in Turkish Journal of Hematology
Verified
Journal Article
Open access
UYUmut Yılmaz
Umut Yılmaz
MDMehmet Sinan Dal
Mehmet Sinan Dal
Turgay UlasTurgay Ulas
Turgay Ulas
EAElif Birtaş Ateşoğlu
Elif Birtaş Ateşoğlu
FKFatma Keklik Karadag
Fatma Keklik Karadag
BFBurhan Ferhanoğlu
Burhan Ferhanoğlu
Large B-cell lymphoma (LBCL) patients who fail frontline therapy (R/R-LBCL) experience highly unfavorable outcomes. The development of T-cell redirecting therapies is rapidly evolving this outlook. However, costs and infrastructural challenges limit access to such innovative therapies. This study was conducted to document the shortcomings of management in the absence of regular access to T-cell redirecting therapies in a contemporary patient population and define subgroups with the most urgent need for accessing innovative treatments. The second-line management and outcomes of a large real-world LBCL cohort from Türkiye were retrospectively analyzed with the participation of nine centers from four different geographical regions. Despite the contemporary period (2012-24), there was no regular access to novel agents. The median PFS-2 was 6.9 months. Less than a quarter of patients (24.3%) received transplantation following a response to second-line therapy, the only subgroup who benefited from the standard care (2-year PFS-2: 67.8%). The remaining 295 patients (75.7% of the cohort) had a median survival of 6.1 months and a 2-year PFS-2 of 10.3%. Progression within a year from diagnosis, non-curative intent at second line, and failure of curative second-line therapy were key adverse features for a dismal prognosis, with median survival durations of 8.8, 2, and 7.4 months, respectively. The current therapeutic strategy of intensive chemoimmunotherapy followed by autologous transplantation yields a reasonable chance of survival for only a fifth of patients. The findings emphasize the urgent need for expanding access to T-cell redirecting approaches in R/R LBCL for early progressors, transplant-ineligible cases, those who fail intensive second-line regimens.

13 February 2025 in Leukemia Research Reports
Verified
Journal Article
Open access
TTTaner Tan
Taner Tan
GGGenco Gençdal
Genco Gençdal
ÜÜÜmit Barbaros Üre
Ümit Barbaros Üre
OAOlga Meltem Akay
Olga Meltem Akay

26 August 2025 in LLM Dergi
Verified
Journal Article
Closed access
TTTaner Tan
Taner Tan
ATAhmet Umur Topcu
Ahmet Umur Topcu
ECErdem Cig
Erdem Cig
ESEfe Semercioğlu
Efe Semercioğlu
EOEmre Osmanbaşoğlu
Emre Osmanbaşoğlu
SBSinem Civriz Civriz Bozdag
Sinem Civriz Civriz Bozdag